Calcitonin, as SMS 201-995, ameliorates the VIPoma syndrome.
A 72-year-old woman was referred to our hospital for diarrhea, abdominal and back pain, weight loss, low serum potassium level. Pathological findings and high circulating Vasoactive Intestinal Peptide (VIP) levels allowed us to diagnose "VIPoma syndrome". The patient underwent a treatment with SMS 201-995 with improvement of symptomatology and reduction of circulating VIP levels. After a wash-out period the patient was treated with salmon calcitonin with a net improvement of diarrhea, normalization of potassium serum level and reduction of VIP level. The symptomatology recurred after calcitonin withdrawal. These data confirm the effectiveness of SMS 201-995 in the VIPoma syndrome and suggest that calcitonin may ameliorate symptomatology and reduce circulating VIP level in patients with VIPoma tumor.
Antonelli
A
A
Istituto di Clinica Medica II, Università di Pisa, Italy.
Gambuzza
C
C
Bertoni
F
F
Baschieri
L
L
D000368:Aged; D002116:Calcitonin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D011188:Potassium / Q000097:blood; D014660:Vasoactive Intestinal Peptide / Q000097:blood; D003969:Vipoma / Q000097:blood / Q000188:drug therapy*
D014660:Vasoactive Intestinal Peptide; C028815:salmon calcitonin; D002116:Calcitonin; D015282:Octreotide; D011188:Potassium